Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy

Clicks: 687
ID: 118797
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #1 of 31 articles by views in Journal of cellular and molecular medicine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
The urokinase-type plasminogen activator (uPA) receptor (uPAR) participates to the mechanisms causing renal damage in response to hyperglycaemia. The main function of uPAR in podocytes (as well as soluble uPAR -(s)uPAR- from circulation) is to regulate podocyte function through αvβ3 integrin/Rac-1. …
Reference Key
m2019journalinhibiting Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Dal Monte M;Cammalleri M;Pecci V;Carmosino M;Procino G;Pini A;De Rosa M;Pavone V;Svelto M;Bagnoli P;;
Journal Journal of cellular and molecular medicine
Year 2019
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.